GLPwatch
Papers (10389)
Page 154 of 174, ranked by citation count.
- Could semaglutide be related to increasing the risk of developing a disordered eating?
- Real world, retrospective experience of glucagon-like peptide-1 receptor agonists in kidney transplant recipients: A single-center case series.
- More on Semaglutide in Early Type 1 Diabetes. Reply.
- Effect of Calorie Restricted Diet Versus Liraglutide on Intrapancreatic Fat Deposition in People With Obesity: A Pilot Study.
- Real-world evaluation of the efficacy and safety of switching from weekly dulaglutide to weekly semaglutide: The SEMA-SWITCH study.
- In symptomatic peripheral artery disease with T2D, semaglutide increased maximum walking distance at 1 y.
- Semaglutid bessert HFpEF-Herzinsuffizienz.
- Real-world effectiveness of oral semaglutide on body weight, composition, and metabolic parameters in patients with obesity without diabetes.
- A retrospective audit of weight loss and health outcomes following bariatric surgery at a tertiary public hospital.
- Introducing an important therapy for obesity to primary care: once-weekly subcutaneous semaglutide 2.4 mg.
- Cardiovascular and brain effects of liraglutide in transthyretin amyloidosis (ATTR) mice models.
- Oral Semaglutide: Balancing Promising Therapeutics with Adverse Effects and Access Barriers.
- Mental health changes after 4 months of weight loss treatment with the glucagon-like peptide-1 analogue liraglutide 3.0 mg.
- Larotrectinib-associated withdrawal symptoms resolved following initiation of GLP-1 receptor agonist: a case report.
- Semaglutide-Induced Weight Loss Is the Main Determinant for the Improvement of Hepatic Biochemistry and Elastographic Repeated Measurements with FibroScan® in Patients with Type 2 Diabetes Mellitus and Metabolic Dysfunction-Associated Steatotic Liver Disease.
- Short-term comparative effects of semaglutide, either alone or in conjunction with canagliflozin, on early diabetic kidney disease.
- Simultaneous Bilateral NAION Following Initiation of High-Dose Semaglutide: A Case Report.
- Trends in Use of Obesity Medications and Metabolic and Bariatric Surgery Among All of Us Participants From 2003 to 2023.
- Glucagon-Like Peptide-1 (GLP-1a) Receptor Agonist Use in Patients Presenting for Gastroenterology Procedures: A Review of Concerns.
- Semaglutide, Obesity-Related Heart Failure, and Type 2 Diabetes.
- [Exendin-4 improves impaired endothelial dependent vasodilation in obese rat].
- [The effect of exenatide analogs on hydruretic function of rat kidney under water load].
- Long-Term Safety and Renal Outcomes of Semaglutide in Non-Diabetic Obesity with Chronic Kidney Disease or Hypertension: A Systematic Review and Meta-Analysis.
- 68 Ga-NODAGA-EXENDIN-4 PET/CT in the Detection or the Exclusion of Occult Sporadic Insulinomas.
- Effects of Glucagon-Like Peptide-1 Receptor Agonists (Mono and Combination Therapy) on Energy Expenditure: A Scoping Review.
- FABP4, marker of worse prognosis in cardiovascular disease, induces neutrophil's proatherogenic phenotype which is modulated by semaglutide.
- Probable Tirzepatide-Induced Rhabdomyolysis in an HIV-Positive Patient.
- [Effects of exendin-4 on rat cardiomyocyte apoptosis early after severe scald injury].
- Semaglutide reduced a composite of CV events at 2 years in patients with type 2 diabetes and high CV risk.
- Differential effects of semaglutide and colchicine on atrial remodeling in rats with reduced ejection fraction after myocardial infarction.
- Semaglutide slows epigenetic aging in a randomized trial of HIV-associated lipohypertrophy.
- A Multicentre, Prospective, Non-Interventional Single-Arm Study Investigating the Impact of Once-Daily Oral Semaglutide in a Real-World Adult Population With Type 2 Diabetes in Mexico.
- Innovative Glucagon-like Peptide 1 Receptor Agonists: Exploring the Therapeutic Potential of Specific Modified Monomer, Dimer, and Tetramer in Type 2 Diabetes Treatment.
- [Effects of semaglutide on mental health].
- Target-mediated drug disposition modeling of liraglutide in rats: Implications of target engagement for pharmacodynamic predictions.
- Semaglutide drives weight loss through cAMP-dependent mechanisms in GLP1R-expressing hindbrain neurons.
- Gewichtsabnahme ist mit Semaglutid signifikant grösser als mit Liraglutid.
- Semaglutide, Obesity-Related Heart Failure, and Type 2 Diabetes.
- Immune-mediated necrotising myopathy following semaglutide treatment: a contributing factor?
- Is Weight Loss the Main Driver for A1C Improvement by Glucagon-Like Peptide 1 (GLP-1) Receptor Agonists? A 2.5-Year Analysis in Real-World Clinical Practice.
- Using real-world data to predict findings of an ongoing phase IV trial: glycemic control of semaglutide versus standard of care.
- Semaglutide attenuates autistic-like behaviors in BTBR mice through the shaping of gut microbiota.
- [Clinical application of exenatide in Japanese patients with type 2 diabetes mellitus].
- Exenatide and sitagliptin: pancreatitis and pancreatic cancer. Harms on the rise.
- The relation between tirzepatide and adverse cardiovascular events or renal adverse events: a meta-analysis based on randomized controlled trials.
- Semaglutide-associated risk of nonarteritic anterior ischemic optic neuropathy in patients with type 2 diabetes: A systematic review and meta-analysis of observational studies.
- GLP-1 Receptors Are Enriched in the Lymphatic Endothelium and Their Pharmacological Activation With Semaglutide Improves the Pumping Capacity of Lymphatic Vessels.
- [Onset of type 1 diabetes after treatment with online-prescribed semaglutide].
- [Semaglutide-induced acute-on-chronic liver failure: A case report and literature review].
- Liraglutide subcutaneous injection for weight loss: where does it fit?
- Pharmacosimilars In Obesity Medicine: Informed Choice, Appropriate Choice.
- Semaglutide exposure in early pregnancy and pregnancy outcomes: A case report and review of literature.
- [Cardiovascular effects of liraglutide therapy in patients with type 2 diabetes : Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER)].
- Insulin degludec/liraglutide (Xultophy 100/3.6) for type 2 diabetes.
- Novo Nordisk pays $58.7m to settle claims of mis-selling liraglutide.
- Semaglutide alleviates age-related dry eye disease by restoring lacrimal gland structure and function.
- Revisional Metabolic and Bariatric Surgery Versus Semaglutide: Which Strategy Has Greater Efficacy for Recurrent Weigh Gain After Primary Bariatric Surgery?
- Exenatide Is Neuroprotective in a New Rabbit Model of Hypoxia-Ischemia.
- Neuroprotective Effects of Semaglutide in Cyclophosphamide-Induced Neuropathy: Restoring SIRT1/AMPK, PI3K/AKT/mTOR, and Antioxidant Pathways.
- Prospective Comparative Analysis of Synchronous Abdominoplasty and Mastopexy in Bariatric and Nonbariatric Massive Weight Loss Patients: Highlighting the Rising Trend of GLP-1 Analog Use.